Anesthetic management of juvenile nasopharyngeal angiofibroma resection.
OBJECTIVE
To evaluate the anesthetic implications of the surgical resection of juvenile nasopharyngeal angiofibroma (JNA).


METHODS
Retrospective study.


METHODS
University-affiliated community hospital.


METHODS
Ten patients undergoing resection of JNA.


METHODS
None.


RESULTS
Data from the records of 10 patients undergoing resection of JNA were reviewed and analyzed with regard to demographics, history of the disease, characteristics of the tumor, surgical resection techniques, and anesthetic management. Patients were age 11 to 29 years. All had nasal obstruction as presenting symptom. There was no intracranial invasion. Eight tumors were resected via a lateral rhinotomy and 2 endoscopically (after embolization of the tumor's feeding vessels). Duration of surgery was 6 +/- 1 hours for rhinotomy and 6 and 6.5 hours for the 2 endoscopic resections. Anesthesia was induced in a rapid-sequence manner. Arterial and central venous catheters were placed in all patients. Mean arterial pressure was targeted to 55 to 65 mmHg by using increasing concentrations of isoflurane. The estimated blood loss was 4,800 +/- 1,600 mL and blood replacement was 3,200 +/- 1,400 mL in the first group. The 2 other patients lost 600 mL and 1,500 mL. Blood replacement in this group was 0 and 700 mL respectively. No mortality or major morbidity occurred.


CONCLUSIONS
Resection of JNA should be considered a major procedure with many anesthetic challenges. Isoflurane may be employed to provide deliberate hypotension.
Ezri
Tiberiu
T
Department of Anesthesia, Edith Wolfson Medical Center, Holon, Israel. ezri@wolfson.health.gov.il
Roth
Yehudah
Y
Geva
Daniel
D
Konichezky
Sergio
S
Marshak
Gabriel
G
Halperin
Doron
D
D000759:Adjuvants, Anesthesia; D000293:Adolescent; D000328:Adult; D018322:Angiofibroma / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D001777:Blood Coagulation / Q000502:physiology; D001794:Blood Pressure / Q000502:physiology; D001810:Blood Volume / Q000502:physiology; D002648:Child; D004329:Droperidol; D004724:Endoscopy; D004844:Epistaxis / Q000097:blood / Q000503:physiopathology / Q000628:therapy; D017707:Erythrocyte Transfusion; D005283:Fentanyl; D005500:Follow-Up Studies; D006801:Humans; D007431:Intraoperative Complications / Q000209:etiology; D008297:Male; D015508:Nasal Obstruction / Q000097:blood / Q000503:physiopathology / Q000628:therapy; D009298:Nasal Polyps / Q000097:blood / Q000503:physiopathology / Q000628:therapy; D009303:Nasopharyngeal Neoplasms / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D011183:Postoperative Complications / Q000209:etiology; D012121:Respiration, Artificial; D012189:Retrospective Studies; D012720:Severity of Illness Index; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000759:Adjuvants, Anesthesia; D004329:Droperidol; D005283:Fentanyl